Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Cost Estimate Should Be Studied By FDA, Rep. Brown Tells Commissioner

Executive Summary

FDA should gather its own data on the cost of drug development rather than repeat the industry estimate of $800 mil. per new molecular entity, Rep. Sherrod Brown (D-Ohio) told an IIR conference on generic drugs Oct. 1 in Washington, D.C
Advertisement

Related Content

R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME
R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME
Advertisement
UsernamePublicRestriction

Register

PS042587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel